DBP International: Dossier for Inofer acquired
In 2019 a clinical study was conducted in a collaboration between Double Bond Pharmaceutical AB ("Double Bond") and Skellefteå Lasarett. The study showed that iron succinate significantly improves iron uptake, iron saturation and iron storage in patients with heart failure and iron deficiency. Today, December 7 2020 Double Bond and Laboratorie X.O (France) signed an agreement for the acquisition and rights of Inofer[©]'s (iron succinate) registration dossier for the Nordic market.
"We are pleased with the positive clinical results of ferrous succinate's use. We strongly believe in the great market potential of the drug" - comments Igor Lokot, CEO at Double Bond - "The purchase of the dossier is the next important step for the development and marketing of the product on the Nordic market".
More about clinical study: https://mb.cision.com/Main/12720/2972792/1151388.pdf
More about Drugsson AB: www.drugsson.com